ImmunoGen inc (NASDAQ:IMGN) currently has a “Hold” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
ImmunoGen inc (NASDAQ:IMGN) lost -1.52 Percent and closed its previous trading session at $10.34. The stock traded with the average Volume of 2.75 Million at the end of last session.
ImmunoGen inc (NASDAQ:IMGN) has the Market Capitalization of 1.4 Billion. The Stock has its 52-week High of $13.41 and 52-Week Low of $ 4.80 and it touched its 52-week high on 03/26/18 and 52-Week Low on 11/03/17
The company reported its last earnings Actual EPS of $-0.3/share. While, the analyst predicted that the company could provide an EPS of $-0.25/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.05/share which shows an Earnings Surprise of -20 Percent.
Sell side analysts plays vital role in buying and selling a stock where 3 analysts rated ImmunoGen inc (NASDAQ:IMGN) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -4.01% where SMA50 and SMA200 are -2.99% and 16.36% respectively.
The company shows its Return on Assets (ROA) value of -48.5%. The Return on Equity (ROE) value stands at 138.5%. While it’s Return on Investment (ROI) value is 371%.
ImmunoGen inc (NASDAQ:IMGN) currently has a Weekly Volatility of 4.74% percent while its Monthly Volatility is at 6.01% percent. While talking about Performance of the Stock, ImmunoGen inc currently has a Weekly performance of -6.34%, monthly performance percentage is 5.19 percent, Quarterly performance is -1.34 percent, 6 months performance shows a percent value of 38.05% and Yearly Performance is 49.42 percent.
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company’s product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.